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The efficiency of a medication or a therapeutic class is usually assessed from Randomized Controlled 
Trials (RCTs) by comparing several “hard” primary or secondary outcomes in persons suffering from a 
specific disease and who are selected on the basis of predefined criteria and further allocated either 
to active therapy or a placebo. These interventional studies are commonly referenced to as “mega-
trials” [1] because generally conducted in large populations of patients as high as 100 000 people. 
After random assignment, the eligible participants are equally distributed into 2 groups and 
submitted to a follow-up period of several months or years. The deleterious or beneficial effects of 
the tested therapy are assessed at end-point by recording and comparing the occurrence of all-cause 
deaths or “hard” cardiovascular outcomes. To enhance the strength of the statistical analysis, the 
clinical outcomes are frequently aggregated into composite endpoints such as “Major Adverse 
Cardiovascular Events” (MACE) that, however, should be examined with a critical view because such 
strategies for handling the data can artefactually lead to significant results that do not reflect the 
truth worthy information provided by the statistical analysis of each event accounted separately. The 
present commentary discusses the results obtained in recent RCTs [2-6] that were conducted with 
glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes. Prior to analyzing the data, 
the main statistical procedures used in interventional trials should be briefly remembered without 
burdening the reader with the details of mathematical manipulations. 
 Analyzing the results with a comprehensive approach  
The analysis of RCTs is usually conducted by determining the incidence rates also referenced to as 
the absolute risks (R1 and R2) of a given clinical outcome in 2 randomly groups of participants 
selected according to whether they were exposed (group 1) or not (group 2) to an active medication. 
The ratio R1/R2 corresponds to the relative risk (RR) of the clinical event in group 1 compared to 
group 2. To address the significance of the reduction in the relative risk it is necessary to complete 
the calculation of the RR with the assessment of its 95% confidence interval (95% CI) aimed at 
providing an estimate of the dispersion of the RR. The value of the 95% CI could be ideally obtained 
from 100 RCTs conducted using strictly similar designs. This complex procedure is routinely bypassed 
by using formulas that allow its assessment from one single trial and with the same accuracy as that 
provided by 100 trials. The result is considered to be statistically significant when the horizontal bar 
that illustrates the 95% CI does not cross the vertical line that corresponds to the neutral result 
defined by a RR equal to 1. This concept can be extended to the Hazard Ratio (HR). For instance, and 
as shown in figure 1, it appears that the results were found to be significant (p < 0.05) for a 
composite of adverse cardiovascular events in some trials where GLP-1 RAs were compared to a 
placebo: the semaglutide (SUSTAIN 6 [2]), liraglutide (LEADER [3]), dulaglutide (REWIND [4]) and 
albiglutide (Harmony Outcomes [6]). In contrast, the results were not statistically significant in 
EXSCEL [5] designed to compare the extended-release preparation of exenatide with a placebo. The 
“p” value is usually considered to be significant when p < 0.05. However, in many situations a 
threshold set at 0.005 or even lower [7,8] would be more appropriate in order to establish the 
statistical significance on stronger basis, especially when large populations are investigated in 
different settings and countries. 
Number Needed-to-Treat for avoiding one adverse event when patients are treated with a given 
medication 
This number, defined by the acronym NNT [9], can be easily determined from the following formula: 
100/(R2-R1). At this point there arises the question as to whether the determinations of relative risks 
and NNT are complementary or not. Consider two trials (A and B) that have yielded similar results in 
terms of RR (0.75). In one of the 2 trials (A) the clinical research was applied to 20 000 subjects who 
were equally and randomly allocated into 2 arms of 10 000 participants (the exposed and non-
exposed patients). The investigators found that an adverse event occurred in 600 and 800 
participants with the active therapy and placebo, respectively, over the 5-year study period. The 
calculated absolute risks are 6% and 8% with a RR value of 0.75 (6%/8%). In trial B 1000 subjects 
were included in each group. The numbers of events were of 240 and 320 with the active therapy 
and placebo, respectively. The calculated absolute risks were 24% and 32% with a RR value of 0.75 
(24%/32%). However the seemingly similar relative risk in the trials A and B can lead to misleading 
conclusions if the analysis remains restricted to the crude data provided by the RR and its reduction 
(- 25%). In contrast the interpretation becomes quite different when the analysis is extended to the 
NNT. In the trial A, the NNT is of 100/8%-6%), i.e. of 50 subjects whereas in the trial B its value is of 
100/(32%-24%), i.e. 12 subjects. This result strongly suggests that the treatment used in the trial B is 
much more efficient than that administered in the trial A, but the study is inconclusive if we limit the 
analysis to the reduction in the relative risk.  
However, the evidence for a difference between the 2 trials can be demonstrated from the 
calcuiation of the “p” value, a measure of the strength of statistical evidence [10]. A popular 
approach of the “p” value is to consider that it is statistically significant when < 0.05 and highly 
significant when < 0.01. Two main factors play a major role in the statistical significance of the RR or 
HR (i) firstly the horizontal distance between its value and 1 (the vertical line of neutrality) and (ii) 
secondly the 95% CI: the smaller the confidence interval, the greater the statistical significance. As 
the 95% CI is inversely related to the number of participants, it can be easily understood that the 
investigators have a tendency to study large populations and to analyze different composites of 
adverse outcomes by bringing together as many categories of clinical events as possible. Such 
procedures help to reinforce the strength of “p” values on the boundaries of statistical significance 
when populations remain relatively small or when adverse events are analyzed separately. One 
example is given in figure 1. The Hazard Ratio (HR) for the expanded composite outcomes is lower in 
SUSTAIN-6 than in Harmony Outcomes (0.74 vs 0.78) but the strength of the “p” value is higher in 
Harmony Outcomes than in SUSTAIN-6 (p = 0.0005 vs p = 0.002). This apparent discrepancy is 
explained by the fact that the 95% CI is smaller in Harmony Outcomes than in SUSTAIN-6: (0.69-0.90) 
vs (0.62-0.89), the difference being due to the larger number of participants enrolled in Harmony 
Outcomes (n = 9473) compared with SUSTAIN-6 (n = 3297). This explains why despite their 
limitations [11,12]“mega-trials” with composites of adverse events as primary end-points are 
presently the “gold standard” for comparing active therapies to a placebo. 
The example of GLP-1 Receptor Agonists with duration of action equal to or longer than 24 hours. 
As mentioned above 5 good quality RCTs [2-6] conducted in type 2 diabetes were selected for testing 
the impact on cardiovascular outcomes of different GLP-1 RAs and for addressing the following 
issues: (i) Are these glucose-lowering agents equivalent or not in terms of cardiovascular effects? (ii) 
Is the calculation of the NNT useful or even mandatory to assert on strong basis the potential 
differences between the analogs? Does it exist a threshold for the NNT above which the treatment 
looses its clinical pertinence? The main characteristics of the 5 selected trials are reported in table 1. 
All analogs are once-weekly preparations, except the liraglutide, a 24-h acting preparation. All 
participants were persons with type 2 diabetes. The treatment with the GLP-1 receptor agonists was 
administered either for primary or secondary preventions of the risk for the development or 
progression of vascular diabetes complications. Patients enrolled within the context of primary 
prevention were free of any established symptoms of cardiovascular diseases but all of them were at 
high cardiovascular risk due to the presence of risk factors such as increased blood pressure and 
dyslipidaemia. 
Effects of GLP-1 receptor agonists on the relative risk for developing adverse events 
The results concerning the expanded composite of cardiovascular events considered as a whole and 
the deaths from cardiovascular cause are shown in figure 1. Most trials indicate a significant 
reduction in the risk of adverse events. SUSTAIN-6 (semaglutide) [2], Harmony Outcomes 
(albiglutide) [6] and LEADER (liraglutide) [3] were associated with the highest significant relative risk 
reduction in terms of expanded composite outcomes. Surprisingly, the results for deaths of 
cardiovascular causes are only significant with the liraglutide (LEADER) [3]. The broadest 
discrepancies were observed in SUSTAIN-6 (semaglutide) [2] and Harmony Outcomes (albiglutide)[6 ] 
because these two studies showed a highly significant reduction for the expanded composite 
cardiovascular outcomes, whereas these two GLP-1 receptor agonists did not produce any significant 
changes in the incidence rate of cardiovascular mortality. One of the explanations for this 
discrepancy can be probably found in the fact that the composite outcomes are not similarly defined 
in all RCTs. In SUSTAIN-6 [2], Harmony Outcomes [6] and LEADER [3], the investigators included 6 
categories of adverse cardiovascular events into the composite outcomes: the deaths from 
cardiovascular causes + non-fatal myocardial infarctions + non-fatal strokes + revascularizations + 
hospitalizations for unstable angina pectoris + heart failure. These studies were the most positive 
(figure 1). In contrast, negative or poorly positive results were observed in EXSCEL [5] and REWIND 
[4] (figure 1), respectively, when the revascularizations and intercurrent hospitalizations for 
cardiovascular purposes were excluded from composite outcomes. Such observations point out the 
difficulties to select appropriate composites because their statistical significance can be rendered 
very unstable according to whether the choice has been or not properly done. 
Effects of GLP-1 receptor agonists on the Number Needed- to- Treat 
Does the estimation of the NNT permit to gain better insights into the questions that have been 
raised by the analysis of relative risks? If we limit our concern to the composite outcomes (table 2) 
the number of subjects to be treated for avoiding a cardiovascular event in one of them steadily 
decreases and thus becomes more and more pertinent across a stepwise decrement from EXSCEL 
(NNT = 125) to SUSTAIN 6 (NNT = 17) with intermediary steps corresponding to REWIND (n = 71), 
LEADER (NNT = 42) and Harmony Outcomes (NNT = 27). Using the same procedure the tabulation 
order for deaths from cardiovascular cause is somewhat different, the best NNT being observed for 
LEADER (NNT = 77) (table 2). The other studies do not provide convincing results because the NNTs 
were above 100 subjects. Therefore the NNT seems to indicate that GLP-1 RAs are not equally 
efficient albeit there is an ongoing debate on an overall class effect [13,14]. 
The argument for using NNT as a marker of therapeutic efficiency despite limitations due to the 
duration of follow-up 
The question that arises from the NNT is to know as to whether there exists a relationship between 
the NNT and the level of the “p” value calculated from the RR or HR. Using the data provided by the 5 
RCTs, the relationship between these two parameters can be depicted by an hyperbolic function 
(figure 2) the NNT becoming greater and greater when the strength of the “p “value becomes less 
and less significant. The coefficient of determination (R2 = 0.68) of the relationship is highly 
significant: p < 0.0001. In addition, the “p” values 0.05 and 0.005 correspond to NNT of 40 and 80 
subjects, respectively. If we consider that a treatment becomes justified when the “p” value is < 
0.005, consequently we suggest that the relevance for a treatment with GLP-1 RAs should be based o 
a NNT < 40. Therefore it appears that only 3 preparations fulfill this condition: the semaglutide (NNT 
= 17), albiglutide (NNT = 27) and liraglutide (NNT = 42). A NNT between 40 and 80 and a fortiori > 80 
raises the question of the pertinence of treatments with GLP-1 RAs. However it should be noted that 
the NNT has to be aligned on the duration of treatment in order to be appropriately interpreted.  
At the end of this commentary article, the following main conclusions can be drawn: 
• The investigators of RCTs should provide all the data related to the analysis of the results in 
order that everyone might be able to do additional calculations such as those of NNT 
• The determinations of relative risks (Risk or Hazard Ratios) and the significances of their 
changes expressed as levels of the “p” value are mandatory but remain insufficient 
• The NNT permits to capture additional information that are likely more meaningful than 
those provided by the RR, HR and 95% CI, which sometimes are pet peeves for some 
healthcare professionals who are unfamiliar with the use of statistics  
• The definition of the composite end points of adverse events in the different trials should be 
more carefully harmonized in order that the data of RCTs become easily comparable [13,15]. 
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Figure 1: Hazard Ratio (HR) and “p” values in 5 Randomized Controlled Trials (RCTs) aimed at 
examining cardiovascular outcomes when different GLP-1 receptor agonists were compared with a 
placebo in type 2 diabetes. The HRs were indicated for an expanded composite of cardiovascular 













Figure 2: Relationship between “p” values and Hazard Ratios (HR) for different cardiovascular events 
(X axis) and the Number Needed-to-Treat (NNT, Y axis) for avoiding one cardiovascular event in one 
of the patients treated with a GLP-1 receptor agonist. To facilitate the illustration the “p” values were 
converted into Log (px104). The “p” threshold set at 0.05 and 0.005 corresponds to NNT of 40 and 80, 
respectively. The grey zones (dark or light) correspond to the different objectives: NNT < 40 or NNT 

















Table 1: Main characteristics of the 5 RCTs involving a comparison between patients with type 2 
diabetes according to whether they were exposed or not to a treatment with different GLP-1 
receptor agonists. The secondary prevention was defined by the presence of at least one 
cardiovascular coexisting condition. The primary prevention was characterized by the lack of any 
evidence of cardiovascular disease at baseline. However due to the presence of risk factors, these 















Table 2: Stratification of the cardiovascular risk by taking into account the HR and NNT in 5 RCTs 
aimed at comparing patients with type 2 diabetes according to whether they were treated or not 
with different GLP-1 receptor agonists. Upper part: statistical risk for a composite of cardiovascular 
outcomes. Lower part: statistical risk for cardiovascular mortality. CRTs = Controlled Randomized 
Trials. NNT = Number Needed-to-Treat for avoiding one adverse event in one of the patients treated 
with the GLP-1 receptor agonist. 
 
 
 
 
